The AOA Dx founding team has worked together for over a decade at two successful women’s health diagnostic startups, both resulting in strategic exits. With more than 30 years of experience bringing products from concept to commercialization across global markets, they’ve assembled a unique team of experts in the field who are dedicated to changing the world of oncology.
Oriana is a visionary leader in the field of women’s health and diagnostics. Recently honored in Inc’s 2022 Top 100 Female Founders for her work in ovarian cancer diagnosis, Oriana brings a wealth of knowledge and expertise bringing disruptive diagnostics to market and changing the landscape of clinical practice. Oriana is passionate about entrepreneurship and problem solving and hopes to use these skills to revolutionize early cancer detection, particularly in cancers that disproportionately affect women.
Oriana has global experience creating and leading organizations resulting in successful strategic exits. Prior to AOA, she led teams at early-stage startups and large life sciences companies. Oriana has a track record of developing a highly productive culture and turning visions into reality. She has a proven technical record of creating market entry strategies and product launches in new markets, including launching nationwide HPV screening in East Africa and novel diagnostics in maternal fetal medicine, oncology and infectious diseases.
As CEO of AOA, her dedication and work have earned her numerous awards and recognition, including the Massachusetts Life Sciences Center MassNextGen Award, The Eddies People’s Choice Award and The Wave Summit’s Emerging Women Founder in Bio Award.
Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.
Alex is a passionate and dedicated business leader with a track record of launching UK medical device and diagnostics sales companies. He has extensive experience priming markets, launching products and driving early product sales.
In most recent roles, Alex has been committed to commercializing and launching innovative, disruptive products through his own businesses across European healthcare markets with a primary focus on obstetrics and gynecology.
Alex works closely with Oriana, ensuring strategies relating to finance, accounting, legal and fundraising are executed in a timely manner. On a daily basis, Alex ensures AOA’s operations are running smoothly and efficiently.
Alex has a degree and MSc from the University of Southampton and University College London.
Anna is an innovator and a dynamic business leader with a passion for advancing healthcare through world-class diagnostics. As the Chief Development Officer of AOA, she is pioneering the development of the groundbreaking GlycoLocateTM platform for early cancer detection by utilizing tumor marker gangliosides and AI to solve some of the most difficult challenges in diagnostics today.
Anna was named to Inc. Magazine’s 2022 Female Founders 100 List. She brings a wealth of experience to AOA having overseen the inclusion of multiple products into national and pan-European guidelines, and she has experience with US FDA submissions for 510(k), PMA, and CLIA LTD regulatory routes.
Anna has a unique global perspective on healthcare having led teams launching paradigm changing diagnostics in women’s health in Europe, the Middle East, Latin America and Asia.
Dr. Margo Harrison MD, MPH, FACOG is joining AOA Dx as Director of Clinical Affairs. After getting her undergraduate degree at Yale University, her medical schooling at Albert Einstein College of Medicine, and her public health degree at Johns Hopkins Bloomberg School of Public, she trained and worked at Columbia University Medical Center followed by University of Colorado (CU) in obstetrics and gynecology. At CU she was a Women’s Reproductive Health Research Fellow (NICHD K12) where she trained in dissemination and implementation science and health outcomes research and was awarded foundation and independent NIH funding (R21). In January 2022 she became adjoint at CU in order to work at Planned Parenthood of the Rocky Mountains and founded her own consulting firm to support women’s health start-ups. She has worked with AOA Dx as a regulatory, grant writing, medical affairs, clinical trial, and business development consultant since November of 2022, and is now joining the team full-time. She enjoys jasmine and matcha green tea, crossfit, and is excited about the puppy she is adopting who is currently en utero (it’s surprise for her 8- and 6-year-old children so don’t say anything!)
Elizabeth is a clinical research professional specializing in the management of clinical operations, quality, and regulatory oversight of global clinical trials in multiple therapeutic areas in biopharmaceutical, medical device and diagnostics.
Elizabeth has extensive experience in all phases of clinical trials that allowed market access for strategic business initiatives. She is Project Management certified through PMI and has been involved in the clinical trial process from development to regulatory approval applying a strong focus on risk and quality oversight.
As Director of Clinical Operations, Elizabeth has overall responsibility for leading AOA’s clinical trial operations.
Elizabeth holds an undergraduate degree in Organizational Leadership and a MSc. in Health Outcomes Research from St. Louis University.
Andrea is a passionate leader who excels at scaling up systems and solutions to create positive outcomes for community stakeholders.
Having graduated from the Boston University Questrom School of Management with a degree in Marketing, she was a 2009 Teach for America Corps member, serving in Chelsea MA.
After spending 13 years working in charter and turnaround schools as a school leader she has pivoted to ensuring behind the scenes operations at AOA Dx run smoothly in order to accomplish our mission critical goals.
While she has worked for AOA part time since 2020, she is excited to support the team full time in finance, HR, marketing, and project management.
Abby is an experienced leader in the field of immunoassay development. Throughout her career, she has developed and overseen the creation of numerous immunoassays, resulting in a deep and comprehensive expertise in the field. Abby’s passion for problem-solving and curiosity has been pivotal in driving her approach to assay development. She excels at tackling complex challenges and applies her analytical thinking skills to develop creative solutions and products.
Prior to joining AOA Dx, Abby led multiplexed immunoassay development projects that became widely utilized research products, making contributions to global health and the advancement of disease understanding. At AOA Dx, she is utilizing her skills to develop AOA’s ovarian cancer diagnostic tests, leveraging her extensive knowledge and experience in the field.
Abby holds degrees in Chemical and Biological Engineering from Utah State University and University of Colorado at Boulder.
Robert is an industrious molecular and cell biology expert with more than a decade of experience conducting research in the areas of biopharmaceutical engineering, genome editing, and cancer cell biology. He has utilized his proficiency in these areas to execute product development strategies within the gene editing space in addition to spearheading research efforts to delineate complex cell signaling pathways for the identification of diagnostic and therapeutic targets to combat cancer. His work has resulted in several publications in Science Advances, Science Signaling, Journal of Cell Biology, and Cancer Research.
As an innovative and dynamic scientist, Robert is committed to solving challenging problems centered around cancer diagnostics and prevention. At AOA Dx, he is using his skills and expertise to develop AOA’s ovarian cancer diagnostic test in conjunction with expanding the GlycoLocate™ platform to enable the detection of additional cancer targets.
Having earned his Ph.D. from Johns Hopkins University in Chemical and Biomolecular Engineering, Robert also holds a B.S. from The Ohio State University in the same discipline graduating “With Research Distinction”.
Rachel is an accomplished expert in metabolomics with over 10 years of mass spectrometry experience. Her previous research focused on studying metabolic alterations in various disease states, including acute myeloid leukemia, Down Syndrome, sickle cell disease, breast cancer, and hemorrhagic shock. Her groundbreaking work on understanding the complex metabolome of acute myeloid leukemia stem cells and other cancers has been published in scientific journals such as Nature Medicine, Nature Cancer, Cell, Cancer Cell, Cell Stem Cell, Blood, and more.
At AOA Dx, Rachel dedicates her expertise to validating a diagnostic test for ovarian cancer and expanding the GlycoLocateTM platform to detect additional cancer targets. Her commitment to cancer diagnostics and prevention fuels her drive to solve challenging problems in the field.
Rachel earned her Ph.D. in Biochemistry from the University of Colorado Anschutz Medical Campus and holds an M.Sc. in Microbiology from the University of Florida, along with a B.S. in Biochemistry and Molecular Biology from Michigan State University. With her multidisciplinary knowledge, scientific acumen, and proven track record, Rachel continues to push the boundaries of cancer research, contributing to advancements in detection and treatment methods.
Dr. Saragovi is a passionate and world-leading scientist in the area of Translational Medicine.
Dr. Saragovi has published over 200 publications and 21 patents, primarily focusing translational medicine. More recently Dr. Saragovi has focused on the targeting of gangliosides, which are used clinically for cancer diagnosis, prognosis, and therapy.
Dr. Saragovi based at McGill University and Lady Davis Institute at the Jewish General Hospital, Montreal.
Surbhi Sarna is the founder and former CEO of nVision medical, a medical device company that, to date, is the only device cleared by the FDA to collect cells from the fallopian tube for the detection of ovarian cancer. Having led the company from inception, nVision Medical was acquired by Boston Scientific in 2018 for $275m.
Most recently Surbhi became Y Combinator’s first-ever partner for healthcare and biotech, and she currently sits on the board of Penumbra, Progenity, Astia, Draper University and the Harker School. Surbhi has extensive experience with early product development, funding, clinical trials and commercialization.
Elizabeth Garner, MD, MPH has over a decade of pharmaceutical development experience. She also has deep expertise in clinical trial design and execution. She has held roles of increasing strategic responsibility in large and small companies, including ObsEva SA, Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics. In addition to Pharm-Olam, she is also on the Boards of the Drug Information Association (DIA) and the American Medical Women’s Association (AMWA), and she was a 2019 awardee of the PharmaVoice 100 most inspiring individuals in the life-sciences industry.
Dr. Garner is currently the Chief Scientific Officer at Ferring Pharmaceuticals, a biopharmaceutical company that focuses on the development of innovative products in the areas of reproductive medicine and maternal health, urology and gastroenterology. Dr. Garner received joint MD and MPH degrees from Harvard Medical School and the Harvard School of Public Health. She was trained in obstetrics and gynecology at Brigham and Women’s/Massachusetts General Hospitals and completed a fellowship in gynecologic oncology at Brigham and Women’s and Dana Farber Cancer Institute.
Amy P.N. Skubitz, Ph.D. is a Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota (UM) and an Adjunct Professor in the Department of Obstetrics, Gynecology, and Women’s Health. Dr. Skubitz serves as the Director of the Ovarian Cancer Early Detection Program (OCEDP) at the UM.
Her research interests include the progression and recurrence of ovarian cancer, which involves its genetic profile and the discovery of new biomarkers by mass spectrometry-based proteomics using a wide variety of biospecimens. Her research studies represent an approach toward understanding the molecular mechanisms modulating the phenotypic behavior of cancer cells with the ultimate goal of designing biomarkers and/or biopharmaceuticals for therapeutic use in cancer.
As a faculty member at the UM for the past 30 years, Dr. Skubitz’s research has been continually funded from a variety of sources. She has published over 125 manuscripts in the field of cancer. She has overseen and supervised many projects with collaborators at the UM, nationally, and internationally.
She established the UM’s Tissue Procurement Facility and served as the Director or Assistant Director for 15 years. She has been a member of the International Society for Biological and Environmental Repositories since 1999, and served on the Education and Training Committee for 6 years.
She has been a mentor to many faculty, postdoctoral fellows, graduate students, undergraduates, and technicians who have performed research projects in her laboratory.
Dr. Kevin Elias is an experienced physician-scientist with a demonstrated history of success in translational medicine and advanced oncologic care. He has years of experience in Medical Education, Clinical Trials & Healthcare Leadership for gynecologic oncology and early cancer detection. Graduating from Harvard College and Vanderbilt University School of Medicine, he completed his residency in OB/GYN at Brigham and Women’s Hospital and fellowships is Gynecologic Oncology and Anesthesia Critical Care Medicine at Brigham and Women’s Hospital. Additionally, he conducted post-doctoral research at Dana-Farber Cancer Institute in molecular biology and MIT in cancer nanotechnology. He is currently an active practicing physician and Director of the Gynecologic Oncology Laboratory at Brigham and Women’s Hospital.
Dr. Kessler is Professor in the Department of Health Systems and Population Health, University of Washington, which he chaired from 2009 – 2015. He has over 40 years of experience in health services research, including positions at the National Institute of Mental Health, National Cancer Institute, and FDA. At NCI, he and his colleagues substantially changed the way in which cancer surveillance is performed, with the addition of the Cancer supplements to the National Health Interview Survey, the SEER-Medicare data system, and the Breast Cancer Screening Consortium and the Breast Cancer Surveillance Consortium. His research record includes focused work in cancer, cancer surveillance research, and regulatory aspects of medical products. He came to UW from U.S. FDA Center for Devices and Radiological Health. His recent collaborative research focuses on patient centered outcomes and comparative effectiveness research. He also serves as Deputy Chair of the MCED Consortium.
